Ubiquitin Proteasome Drugs: Cancer and Neurodegenerative Disorder Markets

Published - Jul 2010| Analyst - Marianna Tcherpakov| Code - PHM066A
Market Research Report Single User License: $2750 Member Price: FREE

Report Highlights

  • There is only one approved UPS product on the market, Velcade, a proteasome inhibitor, with total sales of more than $1.4 billion in 2009. This drug is expected to be worth $3 billion in 2015, a compound annual growth rate (CAGR) of 13.5% over the study period.
  • In the U.S., Velcade was worth $468 million in 2009 and is expected to reach $1 billion in 2015, a compound annual growth rate (CAGR) of 13.5%. 
  • Worldwide, Velcade was valued at $933 million in 2009 and is expected to reach $2 billion by 2015, a compound annual growth rate (CAGR) of 13.6%.



This BCC Research report, Ubiquitin Proteasome Drug Discovery: Cancer and Neurodegenerative Markets, provides an overview of the current state of drug discovery in the ubiquitin proteasome research field, existing products on the market, and detailed analysis of the competitive environments, including new potential markets for current research projects. The study includes information about significant players in this field of study, trends, and challenges, and other information affecting drug discovery in the ubiquitin proteasome system (UPS).

The scientists who discovered the UPS were awarded the Nobel Prize in Chemistry in 2004. UPS represents one of the most-studied and challenging areas in basic and applicable science. Since 2004, ubiquitin ligases and proteasome function have become one of the major targets for pharmaceutical and drug development companies.
Yet, despite the accumulation of basic knowledge about the mechanism of action of this cellular phenomenon, progress in drug screening and therapeutic development has been delayed. However, the proven success of the proteasome inhibitor bortezomib in addition to a recent breakthrough in the identification of new drug candidates in the UPS research field bring new excitement and hope for further successful drug development. More importantly, the real commercial potential of this research area has not yet been fully acknowledged.
This study will provide knowledge of the current state of drug discovery in this field and new technologies in assay development, and, more importantly, will describe potential novel commercial venues in this drug discovery.
This subject is relatively new to the market research report format and provides business tools to evaluate new commercial opportunities in the drug discovery field. The geographic scope of this study covers U.S. and global companies. The report identifies two major research trends in UPS: proteasome inhibitors versus ubiquitination reaction components as drug targets. This study describes current products in each area, identifies current market participants and, most importantly, notes the trends that are going to affect further drug development in this area. The report also provides information about less-developed areas of UPS, and gives a list of current companies that have new UPS-related products in development.
The research methodology used in this report has been qualitative in nature and has employed a triangulating approach, which aids in validity. Initially, a comprehensive and exhaustive search of the literature on drug discovery and already-marketed products was conducted. These secondary sources included drug discovery and science-related journals, textbooks, press releases, marketing literature, other product/promotional literature, annual reports, security analyst reports, and other publications. A patent search and analysis were also conducted.
In a second phase, a series of semistructured interviews were conducted with company representatives, bench scientists, marketing representatives, and other personnel at biotech and pharmaceutical companies. Other resources included academics, technology, and consulting companies. These were rich sources of data. Subsequent analysis of the documents and interview notes was iterative.
This report is intended for business development professionals, entrepreneurs, and other investment groups so that they can fully understand and evaluate a new, less-familiar area of drug discovery and development. It provides companies’ corporate development departments new insight into competitors’ positions and shows new opportunities otherwise overlooked or less known to the public.
Dr. Marianna Tcherpakov has more than 7 years’ experience as a bench scientist specializing in the area of UPS research. She has contributed to a number of scientific publications and holds several patents. She has expertise as an assay development scientist and is familiar with this research field’s trends and likely future developments.

BCC offers an online information retrieval service. BCC’s home page, located at www.bccresearch.com, enables readers to:

  • Examine BCC’s complete catalog of Market Research Reports and place direct orders
  • Subscribe to any of BCC’s many industry newsletters
  • Read announcements of recently published reports and newly launched newsletters
  • Register for BCC’s well-known conferences
  • Request additional information on any BCC product
  • Take advantage of special offers
The information developed in this report is intended to be as reliable as possible at the time of publication and of a professional nature. This information does not constitute managerial, legal, or accounting advice; nor should it serve as a corporate policy guide, laboratory manual, or an endorsement of any product, as much of the information is speculative in nature. The author assumes no responsibility for any loss or damage that might result from reliance on the reported information or its use.

Table of Contents & Pricing

All reports provided in PDF format. For shared licensing options (5+ Users), please call a representative at (+1) 781-489-7301 or contact us at info@bccresearch.com
Note: Reports are discounted or included with certain Memberships. See Membership Options.

Need a custom data table, graph or complete report? Tell us more.

Contact Us
Share This Report